SLC35C1 and congenital disorder of glycosylation: However, oral fucose supplementation has proven to be an effective therapy for SLC35C1-CDG (LAD II) and GFUS-CDG patients with defects in GDP-fucose transportation or de novo synthesis (CDG: congenital disorders of glycosylation) [16].